Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons - read this article along with other careers information, tips and advice on BioSpace
Share:
Conference Call Scheduled for 4:30 p.m. ET today
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with $260 million in cash and marketable securities, which is expected to fund operations until the end of 2022. Geron s vision is to be recognized as a leader in the treatment of hematologic malignancies by changing the course of these diseases and thereby improving and extending the lives of patients, said John A. Scarlett, M.D., Chairman and Chief Executive Officer. In 2020, we made important progress toward realizing that vision through two ongoing Phase 3 clinical trials, presentation of new data and analyses providing strong evidence of imetelstat s disease-modifying potential that differentiates imetelstat from